Invitae Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVTA research report →
About the company
Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators.
- CEO
- Kenneth D. Knight
- IPO
- 2015
- Employees
- 1,700
- HQ
- San Francisco, CA, US
Price Chart
- Market Cap
- $5.44M
- P/E
- -0.00
- P/S
- 0.01
- P/B
- 0.04
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
- Gross Margin
- 19.18%
- Op Margin
- -138.34%
- Net Margin
- -601.64%
- ROE
- -201.69%
- ROIC
- -37.74%
- Revenue
- $516.30M · 12.13%
- Net Income
- $-3,106,293,000 · -719.59%
- EPS
- $-13.18 · -632.22%
- Op Income
- $-714,236,000
- FCF YoY
- 11.11%
- 52W High
- $2.34
- 52W Low
- $0.01
- 50D MA
- $0.46
- 200D MA
- $0.84
- Beta
- 1.59
- Avg Volume
- 12.70M
Get TickerSpark's AI analysis on NVTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 20, 23 | Nussbaum Robert L | other | 17,404 |
| Dec 20, 23 | Brida Thomas | other | 17,404 |
| Nov 13, 23 | Sholehvar David | other | 850,000 |
| Nov 13, 23 | Sholehvar David | other | 0 |
| Oct 18, 23 | Brida Thomas | other | 229,500 |
| Oct 2, 23 | Schrank Ana J. | other | 850,000 |
| Oct 2, 23 | Schrank Ana J. | other | 0 |
| Sep 23, 23 | Guigley Robert M. | other | 850,000 |
| Sep 5, 23 | Guigley Robert M. | other | 0 |
| Aug 14, 23 | Dickey Robert IV | other | 0 |
Our NVTA coverage
Recent articles, reports, and earnings notes.
No research on NVTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVTA report →Similar companies
Peers in the same neighborhood.